Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $24.00 price target on the stock.

A number of other research firms also recently weighed in on CMPX. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Monday. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Trading Up 1.7 %

CMPX opened at $1.78 on Monday. The stock’s 50 day simple moving average is $2.33 and its 200-day simple moving average is $2.09. The stock has a market cap of $246.14 million, a PE ratio of -4.81 and a beta of 1.40. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In other Compass Therapeutics news, insider Jonathan Anderman bought 20,000 shares of the company’s stock in a transaction on Monday, April 7th. The stock was bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the transaction, the insider now owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Insiders own 28.50% of the company’s stock.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MPM Bioimpact LLC increased its stake in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after acquiring an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC acquired a new position in Compass Therapeutics during the fourth quarter valued at approximately $11,293,000. Tang Capital Management LLC increased its stake in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP raised its holdings in Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock worth $8,380,000 after purchasing an additional 150,336 shares during the period. Finally, Blue Owl Capital Holdings LP boosted its position in shares of Compass Therapeutics by 2.6% during the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock worth $4,284,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.